close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.660 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Via ACCESSWIRE
News headline image
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Via ACCESSWIRE
News headline image
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Via ACCESSWIRE
News headline image
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Via ACCESSWIRE
News headline image
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Via ACCESSWIRE
News headline image
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Via ACCESSWIRE
News headline image
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Via ACCESSWIRE
News headline image
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Via ACCESSWIRE
News headline image
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
Via ACCESSWIRE
News headline image
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
News headline image
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
News headline image
CureVac Announces Update to the Management Team
Via ACCESSWIRE
News headline image
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
Via ACCESSWIRE
News headline image
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
Via ACCESSWIRE
News headline image
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
Via ACCESSWIRE
News headline image
CureVac Announces Voting Results of General Meeting
Via ACCESSWIRE
News headline image
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Via ACCESSWIRE
News headline image
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
News headline image
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
Via ACCESSWIRE
News headline image
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
Via ACCESSWIRE
News headline image
CureVac Announces Voting Results of Extraordinary General Meeting
Via ACCESSWIRE
News headline image
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
Via ACCESSWIRE
News headline image
CureVac Announces Proposed Public Offering of Common Shares
Via ACCESSWIRE
News headline image
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Via ACCESSWIRE
News headline image
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today